company background image
BLUE

bluebird bio NasdaqGS:BLUE Stock Report

Last Price

US$5.77

Market Cap

US$445.0m

7D

-6.5%

1Y

-69.6%

Updated

28 Sep, 2022

Data

Company Financials +
BLUE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

BLUE Stock Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases.

bluebird bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bluebird bio
Historical stock prices
Current Share PriceUS$5.77
52 Week HighUS$25.39
52 Week LowUS$2.87
Beta1.16
1 Month Change-2.20%
3 Month Change39.37%
1 Year Change-69.60%
3 Year Change-93.33%
5 Year Change-95.54%
Change since IPO-78.56%

Recent News & Updates

Sep 26

Bluebird bio names interim finance chief

Gene therapy developer bluebird bio, Inc. (NASDAQ:BLUE) has named Katherine Breedis, formerly the Chief Financial Officer Consultant at Danforth Advisors, as the company’s interim Chief Financial Officer replacing the outgoing CFO Jason Cole. Ms. Breedis has also been named as BLUE’s principal financial officer and principal accounting officer, and her appointments will take effect on Oct. 14 when Mr. Cole departs. Ms. Breedis, who has worked as a CFO consultant for Danforth since Jul. 2021, served as a consultant to BLUE after the company struck a consulting agreement with the advisory firm in May. Mr. Cole’s departure came less than a month after the FDA approved BLUE’s β-thalassemia therapy Zynteglo in August, making it the priciest treatment in history at the time.

Sep 19

Bluebird bio jumps 17% on FDA approval of new gene therapy

The commercial-stage biotech bluebird bio, Inc. (NASDAQ:BLUE) added ~17% pre-market Monday after the company announced the FDA approval of its gene therapy Skysona to address the impact of a rare neurodegenerative disease called cerebral adrenoleukodystrophy (CALD). According to the late Friday press release, the drug, also known as elivaldogene autotemcel (eli-cel), will be indicated in the U.S. to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active CALD. With the FDA approving Skysona under the agency’s accelerated approval pathway, BLUE has agreed to deliver long-term clinical data on the treatment to the regulator, including data from an ongoing long-term follow-up study and commercially treated patients. The company expects the drug to be commercially available by the end of 2022 at a list price of $3.0M. Concurrently, BLUE confirmed that the FDA had lifted the clinical hold on the eli-cel development program. In August, Cambridge, Massachusetts-based biotech won FDA approval for another gene therapy known as Zynteglo for β-thalassemia which it priced at $2.8M.

Shareholder Returns

BLUEUS BiotechsUS Market
7D-6.5%2.9%-2.0%
1Y-69.6%-24.2%-20.3%

Return vs Industry: BLUE underperformed the US Biotechs industry which returned -27.4% over the past year.

Return vs Market: BLUE underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is BLUE's price volatile compared to industry and market?
BLUE volatility
BLUE Average Weekly Movement16.5%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: BLUE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: BLUE's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1992518Andrew Obenshainhttps://www.bluebirdbio.com

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.

bluebird bio, Inc. Fundamentals Summary

How do bluebird bio's earnings and revenue compare to its market cap?
BLUE fundamental statistics
Market CapUS$444.99m
Earnings (TTM)-US$507.45m
Revenue (TTM)US$6.09m

73.1x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLUE income statement (TTM)
RevenueUS$6.09m
Cost of RevenueUS$323.29m
Gross Profit-US$317.20m
Other ExpensesUS$190.25m
Earnings-US$507.45m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-6.58
Gross Margin-5,209.41%
Net Profit Margin-8,333.90%
Debt/Equity Ratio0%

How did BLUE perform over the long term?

See historical performance and comparison